Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd researches and develops, produces, and sells Chinese patent medicines in China. It offers orthopedic, cardiovascular, cerebrovascular, digestive, respiratory, pediatrics, gynecology, hepatobiliary, rheumatism and bone injury, tonic, heat-clearing and detoxifying, and liver and gallbladder drugs, as well as supplements and traditional Chine… Read more
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A (002864) - Total Liabilities
Latest total liabilities as of September 2025: CN¥715.31 Million CNY
Based on the latest financial reports, Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A (002864) has total liabilities worth CN¥715.31 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A - Total Liabilities Trend (2013–2024)
This chart illustrates how Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A Competitors by Total Liabilities
The table below lists competitors of Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Anhui Wantong Technology Co Ltd
SHE:002331
|
China | CN¥1.29 Billion |
|
GBank Financial Holdings Inc. Common Stock
OTCQX:GBFH
|
USA | $1.14 Billion |
|
Porter Holding International Inc
PINK:ULNV
|
USA | $4.03 Million |
|
Oma Saastopankki Oyj
HE:OMASP
|
Finland | €6.78 Billion |
|
Tubacex S.A
MC:TUB
|
Spain | €822.94 Million |
|
BTS Group AB (publ)
OTCGREY:BGPBF
|
USA | $1.52 Billion |
|
Shenmao Technology Inc
TW:3305
|
Taiwan | NT$6.38 Billion |
|
SG Fleet Group Ltd
AU:SGF
|
Australia | AU$2.91 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A (2013–2024)
The table below shows the annual total liabilities of Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥642.84 Million | +12.04% |
| 2023-12-31 | CN¥573.76 Million | -41.64% |
| 2022-12-31 | CN¥983.18 Million | +88.00% |
| 2021-12-31 | CN¥522.97 Million | +22.51% |
| 2020-12-31 | CN¥426.89 Million | +67.95% |
| 2019-12-31 | CN¥254.17 Million | +23.24% |
| 2018-12-31 | CN¥206.24 Million | +4.51% |
| 2017-12-31 | CN¥197.34 Million | +11.70% |
| 2016-12-31 | CN¥176.68 Million | +22.32% |
| 2015-12-31 | CN¥144.44 Million | -6.85% |
| 2014-12-31 | CN¥155.06 Million | +17.88% |
| 2013-12-31 | CN¥131.55 Million | -- |